Literature DB >> 21655659

Identification of different subtypes of breast cancer using tissue microarray.

M A Munirah1, M A Siti-Aishah, M Z Reena, N A Sharifah, M Rohaizak, A Norlia, M K M Rafie, A Asmiati, A Hisham, I Fuad, N S Shahrun, S Das.   

Abstract

Breast cancer may be classified into luminal A, luminal B, HER2+/ER-, basal-like and normal-like subtypes based on gene expression profiling or immunohistochemical (IHC) characteristics. The main aim of the present study was to classify breast cancer into molecular subtypes based on immunohistochemistry findings and correlate the subtypes with clinicopathological factors. Two hundred and seventeen primary breast carcinomas tumor tissues were immunostained for ER, PR, HER2, CK5/6, EGFR, CK8/18, p53 and Ki67 using tissue microarray technique. All subtypes were significantly associated with Malay ethnic background (p=0.035) compared to other racial origins. The most common subtypes of breast cancers were luminal A and was significantly associated with low histological grade (p<0.000) and p53 negativity (p=0.003) compared to HER2+/ER-, basal-like and normal-like subtypes with high histological grade (p<0.000) and p53 positivity (p=0.003). Luminal B subtype had the smallest mean tumor size (p=0.009) and also the highest mean number of lymph nodes positive (p=0.032) compared to other subtypes. All markers except EGFR and Ki67 were significantly associated with the subtypes. The most common histological type was infiltrating ductal carcinoma, NOS. Majority of basal-like subtype showed comedo-type necrosis (68.8%) and infiltrative margin (81.3%). Our studies suggest that IHC can be used to identify the different subtypes of breast cancer and all subtypes were significantly associated with race, mean tumor size, mean number of lymph node positive, histological grade and all immunohistochemical markers except EGFR and Ki67.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21655659

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  6 in total

Review 1.  Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.

Authors:  Sayem Miah; Charles A S Banks; Mark K Adams; Laurence Florens; Kiven E Lukong; Michael P Washburn
Journal:  Mol Biosyst       Date:  2016-12-20

2.  Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

Authors:  Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

3.  Molecular portrait-based correlation between primary canine mammary tumor and its lymph node metastasis: possible prognostic-predictive models and/or stronghold for specific treatments?

Authors:  Germana Beha; Barbara Brunetti; Pietro Asproni; Luisa Vera Muscatello; Francesca Millanta; Alessandro Poli; Giuseppe Sarli; Cinzia Benazzi
Journal:  BMC Vet Res       Date:  2012-11-12       Impact factor: 2.741

4.  Tumor microenvironment-associated modifications of alternative splicing.

Authors:  Jean-Philippe Brosseau; Jean-François Lucier; Hanad Nwilati; Philippe Thibault; Daniel Garneau; Daniel Gendron; Mathieu Durand; Sonia Couture; Elvy Lapointe; Panagiotis Prinos; Roscoe Klinck; Jean-Pierre Perreault; Benoit Chabot; Sherif Abou-Elela
Journal:  RNA       Date:  2013-12-11       Impact factor: 4.942

5.  Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size

Authors:  Yeni Rahmawati; Yunita Setyawati; Irianiwati Widodo; Ahmad Ghozali; Dewajani Purnomosari
Journal:  Asian Pac J Cancer Prev       Date:  2018-01-27

6.  The circular RNA circEIF3M promotes breast cancer progression by promoting cyclin D1 expression.

Authors:  Xiujuan Li; Zhaojun Ren; Yufeng Yao; Jun Bao; Qiao Yu
Journal:  Aging (Albany NY)       Date:  2020-07-11       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.